Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Angiogenesis
|
March 21, 2007
Ocular drug development--future directions
David Sherris
Journal of Ophthalmology
|
December 2, 2011
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy
Jorge L Jacot, David Sherris
Facial Plastic Surgery & Aesthetic Medicine
|
May 2, 2026
Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes
Ariel Harsinay, Mattie Rosi-Schumacher, Nicole Favre, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 22, 2011
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates
Fan Lin, David Sherris, Jos H Beijnen, et al.
Biomed Research International
|
September 13, 2014
Advances in prostate cancer research and treatment
Lorenzo Livi, Andrea M Isidori, David Sherris, et al.
Molecules (Basel, Switzerland)
|
July 5, 2018
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1
Ming He, Qianyi Yang, Allison B Norvil, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
January 22, 2026
Nationwide Adherence to Bell's Palsy Clinical Practice Guidelines: Retrospective Analysis Using a Large-Scale EHR Database
Nicole Favre, Ariel Harsinay, Mattie Rosi-Schumacher, et al.
International Journal of Cancer
|
February 26, 2013
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2
Fan Lin, Levi Buil, David Sherris, et al.
Cancer Research
|
November 18, 2008
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability
Qi Xue, Benjamin Hopkins, Carole Perruzzi, et al.
Journal of Cellular Biochemistry
|
January 13, 2017
The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation
Keith T Ferguson, Elizabeth E Torr, Ksenija Bernau, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Angiogenesis
|
March 21, 2007
Ocular drug development--future directions
David Sherris
Journal of Ophthalmology
|
December 2, 2011
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy
Jorge L Jacot, David Sherris
Facial Plastic Surgery & Aesthetic Medicine
|
May 2, 2026
Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes
Ariel Harsinay, Mattie Rosi-Schumacher, Nicole Favre, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
November 22, 2011
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates
Fan Lin, David Sherris, Jos H Beijnen, et al.
Biomed Research International
|
September 13, 2014
Advances in prostate cancer research and treatment
Lorenzo Livi, Andrea M Isidori, David Sherris, et al.
Molecules (Basel, Switzerland)
|
July 5, 2018
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1
Ming He, Qianyi Yang, Allison B Norvil, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
January 22, 2026
Nationwide Adherence to Bell's Palsy Clinical Practice Guidelines: Retrospective Analysis Using a Large-Scale EHR Database
Nicole Favre, Ariel Harsinay, Mattie Rosi-Schumacher, et al.
International Journal of Cancer
|
February 26, 2013
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2
Fan Lin, Levi Buil, David Sherris, et al.
Cancer Research
|
November 18, 2008
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability
Qi Xue, Benjamin Hopkins, Carole Perruzzi, et al.
Journal of Cellular Biochemistry
|
January 13, 2017
The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation
Keith T Ferguson, Elizabeth E Torr, Ksenija Bernau, et al.
Page
of 2